Summary

On January 17, 2024, Belgium inaugurated its new Health Data Agency, a project approved a year earlier. The agency is designed to improve the accessibility and reusability of health data for secondary purposes. This enhancement of data availability will be executed in a manner that ensures both security and adherence to privacy regulations.

Data types Involved

The data encompasses a broad spectrum. Founding members of the ADS (Sciensano, INAMI, SPF Public Health, KCE, AFPMS) have established a framework to map out the extensive data sets targeted, which include health, diseases, medical equipment and products, health determinants, related activities, etc. According to an agency program manager, this data will inherently be public and anonymized.

Structure of the Repository

The platform, as it currently stands, is relatively straightforward. It lists a variety of accessible datasets, while the agency itself does not hold the data. The data is organized using the DCAT_AP format.

Role of the Health Data Agency

The agency acts as an intermediary, facilitating the interaction between those who reuse data and the entities that own it. It offers tools and legal advice to aid in data exchange. Moreover, the agency is responsible for verifying the identity and intentions of data reusers, aligning its operations with the guidelines set forth by the European Health Data Space.

For further details, visit the Agency's website: https://hda.belgium.be/fr.

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Home

Discover our latest articles

View All Blog Posts
July 16, 2025
Clinical Trial Sponsor
Clinical Trials

Data Protection Strategies for Phase III Clinical Trials

Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.

June 10, 2025
AI
USA
Biotech & Healthtech

Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2

Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.